The Technical Analyst
Guardant Health Inc [GH]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Guardant Health Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-3.60% $16.07
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 955.93 mill |
| EPS: | -4.28 |
| P/E: | -3.75 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 121.71 mill |
| Avg Daily Volume: | 1.997 mill |
| RATING 2024-04-19 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.75 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.20x |
| Company: PE -3.75 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 14.99 - 17.15 ( +/- 6.72%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Tariq Musa | Sell | 249 | Restricted Stock Units |
| 2024-04-15 | Tariq Musa | Buy | 249 | Common Stock |
| 2024-04-15 | Saia John G. | Buy | 7 569 | Common Stock |
| 2024-04-15 | Saia John G. | Sell | 2 701 | Common Stock |
| 2024-04-15 | Saia John G. | Sell | 1 108 | Common Stock |
| INSIDER POWER |
|---|
| -46.43 |
| Last 99 transactions |
| Buy: 864 284 | Sell: 2 349 747 |
Forecast:
16:00 - $16.09
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $16.09
Forecast 2: 16:00 - $16.09
Forecast 3: 16:00 - $16.09
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $16.07 (-3.60% ) |
| Volume | 1.855 mill |
| Avg. Vol. | 1.997 mill |
| % of Avg. Vol | 92.89 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $22.26 | N/A | Active |
|---|
GH
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-18 16:05:00 - Press Release
Guardant Health To Report First Quarter 2024 Financial Results On May 9, 2024
Palo alto, calif.--(business wire)--guardant health, inc. (nasdaq: gh), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on thursday, may 9, 2024. company management will webcast a corresponding conference call beginning at 1:30 p.m. pacific time / 4:30 p.m. eastern time. live audio of the webcast will be available on the “investors” section of the company website at: www.guardanthealth.com. the webcast will be.
2024-04-03 08:05:00 - Press Release
Guardant Health To Present Data Highlighting Application Of Epigenomics To Advance Precision Oncology At 2024 Aacr Annual Meeting
Palo alto, calif.--(business wire)--guardant health, inc. (nasdaq: gh), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 american association for cancer research (aacr) annual meeting, april 5-10 in san diego. multiple poster sessions will report on the utility of using the guardant infinity™ platform across the continuum of cancer care, ranging from pred.
2024-03-13 17:00:00 - Press Release
Guardant Health Eclipse Study Data Demonstrating Efficacy Of Shield Blood-based Test For Colorectal Cancer Screening To Be Published In The New England Journal Of Medicine
Palo alto, calif.--(business wire)--eclipse study to be published in nejm shows shield blood-based screening test detects 83% of people with colorectal cancer.
2024-03-06 16:30:00 - Press Release
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Palo alto, calif.--(business wire)--guardant health, inc. (nasdaq: gh), a leading precision oncology company, today announced that on february 15, 2024, the compensation committee of guardant's board of directors approved the granting of restricted stock units (“rsus”) representing 218,236 shares of its common stock to 82 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 29,048 shares of its common stock to one new non-executive employee with a grant.
2024-03-01 05:30:00 - Press Release
New Survey: Patients And Physicians Overwhelmingly Agree Blood Tests Could Help Close The Colorectal Cancer Screening Gap
Palo alto, calif.--(business wire)--guardant health, inc. (nasdaq: gh), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (crc) screening gap by offering a more pleasant and convenient option. conducted by the harris poll, the ‘closing the gap: crc screening insights' survey was commissioned by guardant health to better understand perceptions and a.
Latest News
2024-04-18 16:05:00 - Business Wire
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be.
2024-04-03 08:05:00 - Business Wire
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego. Multiple poster sessions will report on the utility of using the Guardant Infinity™ platform across the continuum of cancer care, ranging from pred.
2024-04-03 05:17:24 - Finbold
The next Nvidia? 3 stocks poised for massive growth in 2024
Starting in 2014, and even more notably in 2016 as Warren Buffett himself chipped in, Apple (NASDAQ: AAPL) became the benchmark company, and investors around the world were trying to find the ‘next Apple.'
2024-04-01 08:35:43 - InvestorPlace
Better Than ChatGPT? New Super AI Bot Says Buy These 3 Stocks.
It's been nearly one and a half years since ChatGPT went live, but it sure doesn't feel like it. ChatGPT has shaken up many sectors, and triggered an AI revolution.
2024-03-22 13:31:40 - Seeking Alpha
Guardant Health: Shield Launch Could Drive Multiple Expansion
GH can prove to the market they have a competitive product in Shield that can gain a foothold in the roughly 50m unscreened CRC patient population. Shield's strongest adherence rate, with the potential for on-par sensitivity submission within 18 months will drive adoption. Currently trading over 1.5 STD below historical discount to Exact Sciences (EXAS), their main comp.
2024-03-06 08:51:56 - Finbold
Top 3 Wall Street stock picks for March
While the stock market is not yet free of recessionary fears and remains affected by high interest rates, 2024 has, so far, brought significant positive developments if things are to be judged by major indices such as the S&P 500 and the Dow Jones Industrial Average (DJIA) which have been running close to record highs with generally favorable forecasts.
2024-02-22 23:43:08 - Seeking Alpha
Guardant Health, Inc. (GH) Q4 2023 Earnings Call Transcript
2024-02-22 20:01:17 - Zacks Investment Research
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
2024-02-22 19:21:24 - Zacks Investment Research
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.36 per share a year ago.
2024-02-22 10:56:14 - Zacks Investment Research
Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 109.9% in Guardant Health (GH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.